Related references
Note: Only part of the references are listed.Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors
Patrick A. Ott et al.
CANCER DISCOVERY (2019)
Turning the corner on therapeutic cancer vaccines
Robert E. Hollingsworth et al.
NPJ VACCINES (2019)
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Karim Vermaelen
FRONTIERS IN IMMUNOLOGY (2019)
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
Brigitte Dreno et al.
LANCET ONCOLOGY (2018)
Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
Robert O. Dillman
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
The complement system in cancer: Ambivalence between tumour destruction and promotion
Srinivas Mamidi et al.
IMMUNOBIOLOGY (2017)
The role of the complement system in cancer
Vahid Afshar-Kharghan
JOURNAL OF CLINICAL INVESTIGATION (2017)
Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate
Christelle Ganneau et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2017)
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
Abhishek D. Garg et al.
TRENDS IN IMMUNOLOGY (2017)
Migrating into the Tumor: a Roadmap for T Cells
Lieke L. van der Woude et al.
TRENDS IN CANCER (2017)
The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity
Daphne Laubreton et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
Sofie Wilgenhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Peptide-based synthetic vaccines
Mariusz Skwarczynski et al.
CHEMICAL SCIENCE (2016)
Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer
Elizabeth Scheid et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen
C. Fu et al.
HLA (2016)
The Quest for Anticancer Vaccines: Deciphering the Fine-Epitope Specificity of Cancer-Related Monoclonal Antibodies by Combining Microarray Screening and Saturation Transfer Difference NMR
Helena Coelho et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
Vashti Irani et al.
MOLECULAR IMMUNOLOGY (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
Geoffrey T. Gibney et al.
CLINICAL CANCER RESEARCH (2015)
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens
Liliana R. Loureiro et al.
BIOMOLECULES (2015)
Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody
Lavakumar Karyampudi et al.
CANCER RESEARCH (2014)
Cytokine Diversity in the Th1-Dominated Human Anti-Influenza Response Caused by Variable Cytokine Expression by Th1 Cells, and a Minor Population of Uncommitted IL-2+IFNγ-Thpp Cells
Nan Deng et al.
PLOS ONE (2014)
Immature truncated O-glycophenotype of cancer directly induces oncogenic features
Prakash Radhakrishnan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer
Daniel Mazal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
Wim H. J. Kruit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
Luca Bologna et al.
JOURNAL OF IMMUNOLOGY (2013)
Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant
Teresa Freire et al.
BLOOD (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model
Siao-Yi Wang et al.
BLOOD (2009)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
Mucin-type O-glycosylation and its potential use in drug and vaccine development
Mads Agervig Tarp et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2008)
A polyvalent vaccine for high-risk prostate patients: are more antigens better?
Susan F. Slovin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+T cells and suggests HLA-based differences in epitope recognition
Eddie A. James et al.
INTERNATIONAL IMMUNOLOGY (2007)
Induction of broadly neutralizing antibodies against measles virus mutants using a polyepitope vaccine strategy
FB Bouche et al.
VACCINE (2005)
A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates
R Lo-Man et al.
CANCER RESEARCH (2004)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: Clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine
SF Slovin et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope
R Lo-Man et al.
JOURNAL OF IMMUNOLOGY (2001)
Immunoreactive T and Tn antigens in malignancy: Role in carcinoma diagnosis, prognosis, and immunotherapy
PR Desai
TRANSFUSION MEDICINE REVIEWS (2000)
Share Paper
